D0865 | dantrolene sodium
| Toxicity | Dose | Time | Species | Model | Method | Action | Positive criterion | Reference |
|---|---|---|---|---|---|---|---|---|
| MEMBRANE POTENTIAL | 4.35±1.73 | human | qHTS-HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 3.46 | human | HepG2 | MMP assay | decrease | IC50 | 163 | |
| MEMBRANE POTENTIAL | 15.52±1.78 | rat | hepatocytes | MMP assay | decrease | IC50 | 163 | |
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
 |
Warning |
Aggregated GHS information provided by 7 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. Reported as not meeting GHS hazard criteria by 1 of 7 companies. For more detailed information, please visit ECHA C&L website Of the 1 notification(s) provided by 6 of 7 companies with hazard statement code(s): H341 (100%): Suspected of causing genetic defects [Warning Germ cell mutagenicity] H351 (100%): Suspected of causing cancer [Warning Carcinogenicity] H361 (100%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity] H373 (100%): Causes damage to organs through prolonged or repeated exposure [Warning Specific target organ toxicity, repeated exposure] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P201, P202, P260, P281, P308+P313, P314, P405, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
 |
Warning |
The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory. H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral] |
P264, P270, P301+P312, P330, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| Organism | Test type | Route | Dose (normalized dose) | Effect | Source |
|---|---|---|---|---|---|
| mouse | LD50 | subcutaneous | > 16gm/kg (16000mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977. | |
| mouse | LD50 | intraperitoneal | 534mg/kg (534mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977. | |
| rat | LD50 | intraperitoneal | 413mg/kg (413mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977. | |
| mouse | LD50 | intravenous | > 50mg/kg (50mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977. | |
| rat | LD50 | intravenous | > 50mg/kg (50mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977. | |
| rat | LD50 | subcutaneous | > 16gm/kg (16000mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977. | |
| women | LDLo | oral | 600mg/kg (600mg/kg) | New York State Journal of Medicine. Vol. 77, Pg. 1759, 1977. | |
| human | TDLo | oral | 320mg/kg (320mg/kg) | JAMA, Journal of the American Medical Association. Vol. 231, Pg. 662, 1975. | |
| mouse | LD50 | oral | 1188mg/kg (1188mg/kg) | Journal of Pharmaceutical Sciences. Vol. 69, Pg. 327, 1980. | |
| rat | LD50 | oral | 7432mg/kg (7432mg/kg) | Kiso to Rinsho. Clinical Report. Vol. 11, Pg. 3065, 1977. | |
| dog | LD50 | oral | > 10550mg/kg (10550mg/kg) | Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 25, Pg. 815, 1994. | |
| 1-((5-(4-Nitrophenyl)furfurylidene)amino)imidazolidine-2,4-dione, sodium salt | 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin sodium | 1-((5-(p-Nitrophenyl)furfurylidene)amino)hydantoin sodium salt hydrate |
| 1-[(5--(p-Nitro-phenyl)-fur-furyl-idene)-amino]-hydan-toin sodium salt | 1-[5-(4-Nitrophenyl)furfurylideneamino]hydantoin Sodium Salt | 1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolidinedione Sodium Salt Hemiheptahydrate |
| 1-[[[5-(4-Nitrophenyl)-2-furanyl]methylene]amino]-2,4-imidazolinedione sodium salt | 14663-23-1 | 2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-, sodium salt |
| 2,4-Imidazolidinedione, 1-(((5-(4-nitrophenyl)-2-furanyl)methylene)amino)-, sodium salt, hydrate (2:7) | 2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-, sodium salt, hydrate; | 24868-20-0 |
| 28F0G1E0VF | 2C14H9N4O5.2Na | 2C14H9N4O5.2Na.7H2O |
| AB0011237 | AKOS015895197 | AKOS015895198 |
| B6329 | C07933 | C14H9N4O5.Na |
| CCG-220291 | CCG-40324 | CHEBI:4318 |
| CHEMBL928 | CPD000326766 | CS-5234 |
| D3996 | DANTROLENE SODIUM | Dantamacrin |
| Dantrium | Dantrix | Dantrolene (sodium) |
| Dantrolene Sodium (anhydrous) | Dantrolene Sodium Hydrate | Dantrolene sodium [USAN:BAN:JAN] |
| Dantrolene sodium anhydrous | Dantrolene sodium hemiheptahydrate | Dantrolene sodium salt |
| Dantrolene sodium salt hemiheptahydrate | Dantrolene, Sodium Salt | EINECS 238-706-8 |
| EU-0100424 | F 440 | F-440 |
| HMS1568L04 | HMS2092N12 | HMS2095L04 |
| HMS3261E10 | HMS3266G14 | HMS3411A14 |
| HMS3675A14 | HMS3712L04 | HMS502M20 |
| HY-14657 | Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-, sodium salt | Hydantoin, 1-((5-(p-nitrophenyl)furfurylidene)amino)-, sodium salt, hydrate (2:7) |
| LS-174074 | LS-76265 | MFCD00079130 |
| MLS000859905 | MLS002153441 | NCGC00093847-01 |
| Ryanodex | SAM002703135 | SMR000326766 |
| Sodium dantrolene | UNII-28F0G1E0VF | anhydrous dantrolene sodium |
| sodium 3-({[5-(4-nitrophenyl)furan-2-yl]methylidene}amino)-2,5-dioxoimidazolidin-1-ide |